Non-obese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.

Marcia McDuffie, MD; University of Virginia
Nelly A. Maybee, MD; University of Virginia
Susanna R. Keller, MD; University of Virginia
Brian K. Stevens; University of Virginia
James C. Garmey, MS; University of Virginia
Margaret A. Morris, Ph.D; University of Virginia
Elizabeth Kropf, BS; University of Virginia
Claudia Rival, Ph.D; University of Virginia
Kaiwen Ma, MD, Ph.D; University of Virginia
Jeffrey D. Carter, BA; University of Virginia
Sarah A. Tersey, Ph.D; University of Virginia
Craig S. Nunemaker, Ph.D; University of Virginia
Jerry L. Nadler, MD; University of Virginia

Running Title: Protection from diabetes by deletion of 12/15 lipoxygenase

Corresponding author:
Jerry L. Nadler, MD
University of Virginia
P.O. Box 801405
Charlottesville, VA 22908

Received for publication 19 June 2007 and accepted in revised form 9 October 2007.
ABSTRACT

Objective: 12/15-lipoxygenase (12/15-LO), one of a family of fatty acid oxidoreductase enzymes, reacts with polyenoic fatty acids to produce pro-inflammatory lipids. 12/15-LO is expressed in macrophages and pancreatic β-cells. It enhances interleukin 12 production by macrophages, and several of its products induce apoptosis of β cells at nanomolar concentrations in vitro. We had previously demonstrated a role for 12/15-LO in β-cell damage in the streptozotocin model of diabetes. Since the gene encoding 12/15-LO (gene designation: Alox15) lies within the ldd4 diabetes susceptibility interval in NOD mice, we hypothesized that 12/15-LO is also a key regulator of diabetes susceptibility in the NOD mouse.

Research Design and Methods: We developed NOD mice carrying an inactivated 12/15-LO locus (NOD-Alox15null) using a ‘speed congenic’ protocol and the mice were monitored for development of insulitis and diabetes.

Results: NOD mice deficient in 12/15-LO develop diabetes at a markedly reduced rate compared to NOD mice (2.5% vs. >60% in females by 30 weeks). Non-diabetic female NOD-Alox15null mice demonstrate improved glucose tolerance, as well as significantly reduced severity of insulitis and improved β-cell mass, when compared to age-matched non-diabetic NOD females. Disease resistance is associated with decreased numbers of islet-infiltrating activated macrophages at 4 weeks of age in NOD-Alox15null mice, preceding the development of insulitis. Subsequently, islet-associated infiltrates are characterized by decreased numbers of CD4+ T cells and increased Foxp3+ cells.

Conclusions: These results suggest an important role for 12/15-LO in conferring susceptibility to autoimmune diabetes in NOD mice through its effects on macrophage recruitment or activation.
T he non-obese diabetic (NOD) mouse is a well-established animal model for Type 1 diabetes mellitus (1). Genetic susceptibility in NOD mice has been mapped to more than 30 genetic regions, currently designated “insulin-dependent diabetes” (idd) loci (2). Susceptibility determinants on mouse chromosome 11 were first recognized by linkage to the microsatellite D11Nds1 after outcross of NOD to the C57BL/10 strain, with C57BL/10 alleles decreasing the severity of insulitis in young mice. Linkage to this region of chromosome 11, designated ldd4 (3), was confirmed in a cross with the NOD-related NOR strain, which is a genetic mosaic of NOD with two non-diabetes-prone mouse strains: C57BL/6 and DBA/2. In this cross DBA/2-derived alleles on chromosome 11 decreased the incidence of diabetes after administration of cyclophosphamide (4). Subsequently, congenic strains generated from crosses with C57L (5,6), C57BL/6 (7), and NOR (4,8) mice demonstrated that the initial mapping results were produced by a cluster of susceptibility loci, now designated ldd4.1, ldd4.2, and ldd4.3 (also designated ldd4a). Functional polymorphisms of both Stat5b and Il12b (encoding the 40 kD chain of interleukin 12, IL-12p40), located at the telomeric and centromeric ends of chromosome 11, respectively, have been identified in NOD mice (9-11) and may have contributed to evidence for linkage on chromosome 11 in the initial C57BL/10 cross. To date, however, no strong candidate genes for the ldd4.1-4.3 loci, mapped to mid-chromosome, have been both identified and validated.

Based on its known functions and its genomic location, the 12/15-LO locus (Alox15) represents an excellent candidate for ldd4.1. Also known as “leukocyte 12-lipoxygenase”, this enzyme catalyzes the oxygenation of polyenoic fatty acids (including arachidonic acid and linoleic acid) to form lipid inflammatory mediators, such as 12-hydroperoxyeicosatetraenoic acid (12-HPETE) and 13-(S)-hydroperoxy-9Z,11E-octadecadienoic acid (13-HPODE). Although 12/15-LO is expressed in other cell types, high levels of mRNA, protein, and enzyme activity are reported in macrophages and pancreatic β-cells from both mice and humans (12,13). 12-HPETE is toxic at physiological levels to β-cells, where it is also converted to a more stable metabolite 12-hydroxyeicosatetraenoic acid (12-HETE) by glutathione peroxidase (GPX) (14). 12-HETE is also directly toxic to β-cells and human islets, markedly decreasing insulin secretory function and increasing β-cell death (13). 12-HETE can be further metabolized to 12-HETRe, which acts as a pro-inflammatory agent and co-localizes with insulin in β-cells (15). 12-HETE can activate NFkB, p38, stress-activated protein kinase JNK1/2 and p21-activated kinases, all possible mediators of cytokine induced β-cell damage (13). It is reasonable to postulate, therefore, the 12/15-LO activity may enhance the susceptibility of pancreatic β-cells to cytotoxic insults.

In addition to its activities in pancreatic β-cells, 12/15-LO regulates pro-inflammatory activity of myeloid cells, including macrophages. Macrophages are present in large numbers adjacent to the islets of young, pre-diabetic NOD mice before the onset of substantial T cell infiltration (16-21), and specific defects in macrophage development and function have been repeatedly demonstrated in NOD mice (6,22-30). Products of 12/15-LO activity stimulate expression of macrophage-derived cytokines, such as IL-12 (31), and these cytokines can up-regulate 12/15-LO expression itself in a positive feedback loop, suggesting that it may also participate in β-cell destruction by enhancing the pro-inflammatory activity of islet-associated macrophages (32-34). A null mutation in mice (Alox15<sup>tm1fun</sup>) reduces the atherogenic effects of loss of ApoE, presumably via demonstrated decreases in production of the arachidonic acid metabolites 12-HETE and 15-HETE in circulating macrophages (35). We have also demonstrated that mice homozygous for 12/15-LO mutation are markedly less susceptible to low-dose-streptozotocin-induced diabetes than wild-type littermates (36). Thus, 12/15-LO may play an important role in enhancing tissue-specific inflammation in multiple settings in vivo.

In order to test the possibility that 12/15-LO may regulate disease susceptibility in the spontaneous diabetes of NOD mice, we generated NOD mice congenic for the Alox15<sup>tm1fun</sup> null mutation. We show that these mice are profoundly resistant to the
Protection from diabetes by deletion of 12/15 lipoxygenase development of diabetes. The decreased incidence of overt diabetes is associated with markedly diminished insulitis, as well as preservation of islet mass and function. Preceding these late events, we find that loss of 12/15-LO activity prevents peri-islet accumulation of activated macrophages that are routinely seen in young NOD mice and leads to a significant decrease in CD4+ T cell infiltration into islets, along with increased numbers of Foxp3+ cells, in mature animals. These findings suggest that 12/15-LO is a major regulator of initiation and progression of insulitis in the NOD mouse through its effects on the accumulation of macrophages in islet tissue and, further, that blockade of 12/15-LO activity may provide a novel strategy for prevention and treatment of Type 1 diabetes.

**METHODS**

**Mice.** A B6.129S2-Alox15<sup>imtFun</sup> male mouse, kindly provided by Dr. Colin Funk (37), was mated with an NOD female, followed by successive backcrosses to NOD males in a "speed congenic" strategy, using mapped polymorphic microsatellites for genotypic selection (panel available upon request to MM). The NOD mice used in this study were obtained from a breeding nucleus at the Barbara Davis Center for Childhood Diabetes (Denver, CO) and have been propagated at the University of Virginia by brother-sister mating since 1993. All mice are bred and maintained in a pathogen-free colony in the Center for Comparative Medicine under protocols approved by the institutional Animal Care and Use Committee using AALAC guidelines.

**Genotyping.** High quality genomic DNA was prepared from tail or liver by standard methods. For all microsatellite analysis, oligonucleotide pairs for mapped loci were used to amplify sequence-specific genomic DNA using a modification of published methods (38). For whole genome scans, fluorochrome-labeled primers were synthesized using oligonucleotide sequences from the public domain (38). Fluor-labeled amplicons were pooled into multiplex sets and analyzed on an automated ABI sequencer using Genescan™ and Genotyper™ software (Applied Biosystems, Foster City, CA). For analysis of individual loci, PCR products amplified with unlabeled primers were separated on a 4% agarose gel and visualized with ethidium bromide. The mutant Alox15 allele was genotyped during backcross breeding using a standard set of primers recognizing a retained neomycin-resistance cassette, using published primer sequences and protocol (IMR0013: 5'-CTTGGGTGGAGAGGCTATTC -3' and IMR0014: 5'-AGGTGAGATGACAGGAGATC-3'; protocol available at the following URL: http://www.jax.org/imr/touchdown.html). For allele-specific genotyping of Alox15, PCR was performed using the following primers: CDF 141: 5'-ATC GCC TTC TTG AGT TC, CDF 233: 5'-TCC TGA ACA GGC CTT GAG AG, and CDF 234: 5'-GAG GCC ACT GGT GAG CAG A (37,39). PCR was performed for 35 cycles using an annealing temperature of 65°C. Products were separated on 1% agarose gel and visualized with ethidium bromide. The mutant allele yields a 700 base-pair (bp) fragment indicating disruption of Alox15, while a 350 bp fragment is generated from the wild-type allele.

**Determination of disease status.** Mice at risk for development of diabetes were screened for polyuria and morning glycosuria beginning at 10 weeks of age. Individuals with urine glucose concentrations >500 mg/dL twice at 24-hour intervals received 0.5 units per day of human Ultralente insulin. After 7 consecutive days of insulin requirement, diabetes was confirmed with a blood glucose measurement using an UltraTouch glucometer (Lifescan, Inc., Milpitas, CA). All mice that required insulin for 7 consecutive days had blood glucose concentrations >300 mg/dL. Mice exhibiting no glycosuria by 210 days of age were euthanized for pancreatic histology after confirmation of normoglycemia (morning blood glucose <140 mg/dL).

**Macrophage isolation and detection of 12/15 LO by immunoblotting and real time PCR.** Male NOD-Alox15<sup>imt</sup> and NOD mice (6-8 months old) were injected with sterile 4% thioglycollate; after 72 hours, cells were pelleted from ascites, washed with RPMI-1640 medium containing 10% FBS and 100u/ml of penicillin/streptomycin containing EDTA, and cultured for 3 hours at 37°C in 5% CO₂. Non-adherent cells were removed by multiple washes with Hank’s buffered
saline. Adherent cells were washed with 10% non-heated FBS and incubated for 2 days with a second wash to remove non-adherent cells after 24 hours. Protein was isolated using CelLytic M Cell Lysis Reagent (Sigma, St. Louis, MO).

For quantitation of 12/15-LO protein, cell lysates from two mice from each strain were pooled and proteins separated by electrophoresis on a 10% polyacrylimide gel (50µg protein per lane). Actin was used as loading control. Primary antibodies: 12/15-LO polyclonal rabbit, affinity purified A2460, BLD B&4 (used at 1:2500; synthesized in the Nadler laboratory). Polyclonal rabbit anti-mouse actin (1:2500; Santa Cruz Biotechnology, Santa Cruz, CA) was used as loading control. Secondary antibodies: anti-rabbit IgG-HRP (1:5000; Santa Cruz).

RNA was isolated from 4% thioglycolate stimulated peritoneal macrophages according to Qiagen RNeasy Mini Kit instructions (including an optional DNase step) right after the completion of incubation period. PCR was performed on Stratagene MX3000P™ with MxPro™ Version 3 software, using the following 12/15-LO primers: forward, 5'‐CTCTCAAGGCCTGTTCAGGA‐3'; reverse, 5'‐GTCCATTGTCCCCAGAACCT‐3', with annealing temperature 62°C and extension temperature of 72°C and final extension of 81°C (40). The concentration of β-actin (forward, 5'-AGAGGGAATCGTGCGTGAC-3'; reverse, 5'-CAAATGATGACTGGCGGT-3', with annealing temperature of 62°C) was no different between the samples from the two strains.

**Metabolic testing.** For testing glucose tolerance, mice were fasted overnight and then injected intraperitoneally with glucose (2g/kg). Blood glucose measurements were performed with a UltraTouch glucometer using blood samples taken from cut tail tips at baseline and at 10, 20, 30, 60, 90 and 120 minutes after the injection of glucose. Fasting plasma insulin was measured in blood obtained from tail veins after an overnight fast, using a commercial insulin radioimmuine assay (Catalog No. SRI-13K, Linco Research Inc., St.Charles, MI). Plasma was also collected during IPGTT at baseline, 10, and 30 minutes for insulin measurements using Ultrasensitive Rat/Mouse Insulin ELISA (Crystal Chem Inc., Downers Grove, IL). HOMA (Homeostasis Model Assessment) was calculated using the following formula: [fasting insulin (µU/ml) x fasting blood glucose (mM)]/22.5.

**Histological scoring for insulitis.** Whole pancreas was spread onto plastic cassettes and fixed for 24 hours in 10% buffered formalin prior to automated processing and embedding in paraffin. Consecutive 4 µM sections (3 per slide) were stained with aldehyde fuchsin and hematoxylin. A single score, indicating average severity of insulitis, was given for each mouse based on evaluation of all islets identified by morphology, using the following scale: 0, no infiltrate; 1, polar infiltrate only; 2, infiltrating cells extending around islet to >50% of its circumference without invasion; 3, invasive insulitis. A β-cell score was determined as a product of the residual total islet mass, estimated as a fraction of that in age- and sex-matched NOD.scid control mice (0.0-1.0) multiplied by the average percentage of aldehyde fuchsin-positive cells per islet relative to control (0-100%). Adjunct perivascular and periductular infiltrates, indicative of total pancreatic inflammation, were also compared using a score of 0 (no evidence of mononuclear cell infiltrate) to 3 (extensive infiltrates associated with pancreatic ducts and blood vessels, independent of local islet tissue, and characterized by displacement of exocrine tissue as well as engorgement of lymphatics) (41).

**Immunofluorescence and immunohistochemistry.** Five-micron sections from flash- frozen pancreas were fixed in a 1:1 mixture of 100% ethanol and acetone, followed by blocking of endogenous biotin. For CD4, sections were incubated in rabbit anti-insulin (1:25 in 2% goat serum; Santa Cruz), followed by amplification with a biotinylated Goat-anti-Rabbit antibody (1:200; Vector Laboratories, Burlingame, CA) and Texas Red-labeled Neutralite-Avidin (1:300; SouthernBiotech, Birmingham, AL) or with FITC-labeled anti-CD4 (1:150; BD Biosciences, San Jose, CA) amplified using the Tyramide FITC amplification system (Perkin Elmer, Waltham, MA). In order to
visualize islet-associated Foxp3, sections were stained for insulin using rabbit anti-insulin as above, followed by Cy2-labeled Goat-anti-Rabbit (1:50, Jackson ImmunoResearch, West Grove, PA). Sections were then incubated with biotin anti-mouse Foxp3 (1:100, eBiosciences, San Diego, CA), followed by amplification with the Tyramide Biotin amplification system (Perkin Elmer) coupled with Texas Red-labeled Neutralite-Avidin. All sections were stained with Hoechst Dye (5mg/ml; Invitrogen, Carlsbad, CA) to visualize nuclei. Stained sections were viewed and photographed on an Olympus BX51WI fluorescence microscope (Olympus, Tokyo, Japan). Excitation light was supplied to the sections by a xenon burner through a filter wheel containing DAPI, FITC, and TRITC filters (Sutter Instrument Company, Novato, CA). Images were taken using a Hamamatsu ORCA-ER monochrome CCD camera (Hamamatsu Photonics, Japan). Data were acquired with IPLab software version 4.0 (Scanalytics, Rockville, MD), and analyzed in NIH Image J (NIH, Bethesda, MD).

For Mac-2 staining, pancreata from 4 week old NOD and NOD-Alox15null mice were fixed with 4% paraformaldehyde by heart perfusion. Tissues were dissected and incubated an additional 1 hour in 4% paraformaldehyde, dehydrated in 70% ethanol and embedded in paraffin. Non-specific background was eliminated by 30-minute incubation in methanol with 0.5% hydrogen peroxide, followed by blocking for one hour in PBS containing 10% normal rabbit serum (NRS) and avidin/biotin blocking reagent (Vector Laboratories). Activated macrophages were identified using rat anti-mouse Mac-2 (1:20000, Accurate Chemical, Westbury, NY), followed by biotinylated anti-rat (mouse adsorbed) IgG (1:200, Vector Laboratories) and Vecstatin Elite® (Vector Laboratories) avidin-biotin-horseradish peroxidase reagent. Bound antibody complexes were visualized with diaminobenzidine hydrochloride in 0.02% hydrogen peroxide. Negative controls were prepared by substituting rabbit IgG for the primary antibody. Slides were scored in blind fashion, using the following criteria: 0, no macrophage staining; 0.5, some staining in islet periphery; 1, one to three macrophages inside islet; 2, four or more macrophages; 3, infiltration of >10% of islet surface.

Statistical analysis. Survival comparisons were analyzed by Log-rank test using MedCalc for Windows®, version 9.2.1.0. Results from glucose tolerance tests were compared using a 2-way ANOVA to compare blood glucose differences with respect to factors of time and mouse strain. Insulin levels during a GTT were compared using an unpaired, one-tailed t-test. Histological scores were compared using an unpaired, two-tailed t-test.

RESULTS

Generation of congenic NOD-B6;129S2-Alox15null mice. A single founder B6;129S2-Alox15null male homoygote (~13% 129S2) (37) was mated to NOD females. Using a panel of 106 informative microsatellites, covering all chromosomes except Y, breeding females were selected for minimal residual donor genome during 4 successive generations of backcross to NOD males. Selection for the primary Alox15 mutation was made using a retained neomycin-resistance cassette. In order to limit the flanking non-NOD alleles, mice from one additional backcross generation (N=39) were selected for a minimal congenic interval, followed by intercross with further selection for flanking microsatellite loci (N=86). The final line carries a non-NOD donor interval, including undefined regions, extending from D11Mit177 to D11Mit245 (65.0 to 76.7 Mb; NCBI, build m36; Fig. 1A). It overlaps the intervals defining ldd4.1 in the C57BL/6 and NOR congenic strains (Figure 1B:I-III), but carries NOD alleles at Il12b and Stat5b (Figure 1A) as well as ldd4.3 (6) (Figure 1B:IV). Alox15 itself clearly resides in the ldd4.1 genetic interval and can be considered a regional candidate gene for ldd4.1. The remainder of the non-NOD interval in the final NOD-Alox15null congenic strain, including the entire ldd4.1 interval, is derived from the 129S2 genetic background.

Diabetes incidence in NOD-Alox15null mice. The cumulative incidence of diabetes in this congenic line is markedly decreased from that in contemporary cohorts of NOD mice (Figure 2 A-B), with only 1 of 40 female NOD-Alox15null homozygotes, and 0 of 33 males, becoming diabetic by 7 months of age (p < 0.0001 and < 0.002 for females and males, respectively, by Log-rank test). For females, the hazard ratio for diabetes is <0.00005
Protection from diabetes by deletion of 12/15 lipoxygenase

Absence of Alox15 gene expression in NOD-Alox15null macrophages. We confirmed the absence of 12/15-LO with both RT-PCR and immunoblotting in macrophages from thioglycolate-elicited peritoneal exudates. As expected, we found high levels of 12/15-LO protein in cells from NOD mice, while it is undetectable NOD-Alox15null. Similarly, we found no evidence of residual mRNA expression using primers spanning intron 2: Figure 2D shows a 750-fold difference in 12/15-LO mRNA abundance between the two strains.

Glucose Tolerance Test. 12/15-LO is expressed at high levels in pancreatic islets, but its normal role in this tissue is unknown. In order to determine whether pancreatic β-cells were less responsive in the absence of 12/15-LO activity, we challenged 8-month-old non-diabetic female NOD and NOD-Alox15null mice with an intraperitoneal glucose tolerance test (IPGTT). As is shown in Figure 3, NOD-Alox15null mice cleared glucose more efficiently than NOD mice. Blood glucose values over the entire time course of the test were lower in the NOD-Alox15null mice compared to non-diabetic NOD controls (p<0.0001 by two-way ANOVA). This result suggested that the NOD-Alox15null mice were either more insulin-sensitive or maintained better β-cell function than NOD mice. Mean fasting blood glucose and insulin levels were similar in the NOD-Alox15null and in the NOD controls (Table 1), resulting in a similar HOMA index (a measure of insulin sensitivity) between the two strains. However, while insulin levels peaked at 10 minutes in both groups, peak insulin concentration was significantly higher in NOD-Alox15null mice than in the NOD group (0.87ng/ml +/- 0.117 vs 0.39ng/ml +/- 0.194, P = 0.04), consistent with better preservation of islet mass and function in older mice from the congenic strain.

Severity of insulitis in NOD-Alox15null mice. As expected, based on improved insulin production in NOD-Alox15null mice after IPGTT, pancreatic histology in non-diabetic NOD-Alox15null females at 30 weeks of age showed a marked reduction in both invasive insulitis and β-cell damage compared to age-matched non-diabetic NOD females. A representative pancreatic section from an NOD-Alox15null female mouse is shown in Figure 4A and demonstrates significant perivascular/periductular mononuclear cell inflammation, but no evidence of invasive insulitis. This contrasts with a representative section from an age-matched non-diabetic female NOD mouse, showing a heavily infiltrated islet with loss of β-cell insulin granules (Figure 4B). Islet-associated infiltrates in NOD-Alox15null mice were almost exclusively limited to polar accumulations of mononuclear cells (average score per pancreas <1.0, on a scale of 0-3), while islets from surviving non-diabetic NOD females at 30 weeks showed invasive insulitis (average score >2.5; P< 0.001; Table 2).

Recruitment of CD4+ T cells and Foxp3+ regulatory T cells in NOD-Alox15null mice. CD4+ cells were also markedly decreased in pancreatic sections from NOD-Alox15null mice. At 9.5 weeks, CD4 staining was much more prevalent in NOD mice (Figure 5A) than NOD-Alox15null mice (Figure 5B). By ~30 weeks of age, we observed accumulations of CD4+ T cells near islets from both NOD and NOD-Alox15null mice (Figures 5C and 5D). However, many more islets were observed in sections from NOD-Alox15null mice (66 islets from 2 NOD-Alox15null mice versus 16 in 2 NOD mice), and a larger percentage of these islets showed no signs of insulitis (~50% of NOD-Alox15null islets versus ~10% of NOD islets). Since increased development and accumulation of regulatory T cells might
provide a mechanism for decreasing both the extent and destructiveness of islet-associated inflammation in NOD-Alox15null mice, we stained sections from 30-week-old mice for Foxp3. Foxp3 is a transcription factor involved in the development of regulatory T cells and is used as a marker for identifying these cells. As shown in Figure 5E, very little Foxp3 staining was typically observed among islets from NOD mice, whereas substantial numbers of Foxp3+ cells were observed among NOD-Alox15null islets with signs of insulitis (Figure 5F). Foxp3+ cells were generally not observed in or near pancreatic islets in the absence of insulitis in either strain (data not shown).

Macrophage infiltration in 4-week-old NOD-Alox15null mice. Early islet invasion by macrophages is a characteristic feature of disease process in NOD mice and precedes accumulation of lymphocytes (18). Since 12/15-LO has been shown to enhance macrophage activation, we postulated that a decrease in the presence of activated macrophages associated with pancreatic islets might be responsible for the reduced severity of insulitis along with an increase in cells with apparent regulatory function in NOD-Alox15null mice. Pancreata from 4-week-old female mice, prior to the development of detectable pancreatic T cell infiltration in the NOD controls, were stained for the macrophage activation marker, Mac-2. Figure 6 shows representative examples of islets from the two strains, with brown staining signifying infiltration with activated macrophages. Using a blinded scoring system we found islet-associated Mac-2-positive macrophages in or around 36% of islets (20/56) from NOD-Alox15null mice, whereas 65% of NOD islets (62/96) were Mac-2-positive (P < 0.001). This difference is also reflected in the mean Mac-2 score for each group: NOD: 0.833 +/− 0.075, NOD-Alox15null: 0.55 +/− 0.097, P=0.02), indicating greater intra-islet accumulation of Mac-2-positive cells in pancreatic sections from NOD mice.

DISCUSSION

Our previous studies had demonstrated that targeted deletion of 12/15-LO in mice with a largely C57BL/6 genetic background resulted in protection from streptozotocin-induced β-cell destruction (36). In this study, we show that deletion of 12/15-LO activity via a congenic strategy is also associated with a decrease in autoimmune diabetes in NOD mice. This finding suggests that 12/15-LO may play a direct role in the development of diabetes in this strain.

As noted in the introduction, Alox15 resides within a previously identified diabetes susceptibility locus, Idd4.1, on mouse chromosome 11. Danska and her colleagues have recently published an elegant and comprehensive analysis of gene expression in the Idd4.1 interval using NOR.NOD-Idd4 congenic mouse lines (42). In these mice, segments of NOD chromosome 11 near Idd4.1 (Figure 1B/III) introduced an increase in spontaneous as well as cyclophosphamide-accelerated diabetes when they were bred onto the normally diabetes-resistant NOR genetic background, which itself is a complex mixture of DBA/2, C57BL/Ks, and NOD. Following demonstration that the Idd4.1 interval carries alleles from the non-diabetes-prone DBA/2 strain in NOD mice, they used microarray expression analysis to identify regional genes with differential expression in NOR and NOD mouse bone-marrow-derived macrophages. Eleven of 52 regional genes were differentially expressed in these strains. Of these genes, the NOD and DBA/2 alleles of Alox15 and the closely linked gene Psmb6, encoding a proteosome component, were also shown to differ in both potential regulatory sequence and predicted amino acid sequence, suggesting that they should be considered the primary regional candidates for controlling diabetes susceptibility in NOR mice. Interestingly, however, comparative sequencing showed that the NOD and C57BL/6 Alox15 alleles appear to be identical at the genomic level. This observation makes it unlikely that this locus is responsible for Idd4 loci mapped using crosses with C57BL/6 mice studied by Delovitch and colleagues (7) (Figure 1B/II) or the original genetic mapping with C57BL/10 (6). Furthermore, Alox15 mRNA is actually increased in disease-resistant NOR mice relative to the diabetes-prone congenic strains, suggesting that any differential effects of 12/15-LO in the NOR congenic strains operates by a different mechanism than that in our 12/15-LO-deficient strain.
All of the models generated to identify specific diabetes susceptibility loci on Chr 11, including ours, have used a congenic strategy because of the lack of NOD-derived embryonic stem cells that are competent for homologous recombination with germ-line transmission of induced mutations. The use of congenic mice inevitably imposes constraints on the interpretation of differences in complex phenotypes, such as autoimmune diabetes, because of the extended regions of allelic variation flanking the gene or locus of primary interest. Even with careful attention to the generation of a pure NOD genetic background, it is clearly possible that non-NOD alleles of more than one gene in the interval flanking the target gene could modify the incidence of diabetes in a congenic strain. During our congenic derivation, we had initially isolated, and bred to homozygosity, a larger fragment from the donor strain that carried both 129S2 and B6 alleles within the 50 Mb interval bounded by D11Mit84 (34.4 Mb, mNCBI 36) and D11Mit33 (81.6 Mb). In these mice, 129S2 alleles extended from the centromeric end of the interval to a recombination point between D11Mit320 and D11Mit364 (70.8 and 72.0 Mb, respectively) with the remaining interval derived from the B6 strain. Homozygous Alox15null congenic mice carrying this longer interval had only a modest decrease in the incidence of diabetes (46% of 41 females observed to 30 weeks of age, compared to an incidence of 65% in a contemporary cohort of NOD female mice). A similar incidence was observed in a small group of mice homozygous for a shorter fragment consisting only of 129S2-derived alleles flanked by D11Mit84 and D11Mit364 (4 of 8 females). In both of these lines, disease incidence in congenic males was modestly decreased relative to that in NOD males (17% for congenic mice vs. 25% for NOD). Taken together with the markedly lower incidence observed in the final NOD-Alox15null line presented in this report, these results strongly suggest that a 129S2-derived susceptibility allele is present for at least one gene in the 30 Mb interval extending from D11Mit84 to D11Mit113. However, we still cannot rule out the possibility that the disease resistance conferred by the smaller congenic interval is enhanced by non-NOD alleles at genes tightly linked but telomeric to Alox15.

One regional gene that might be postulated to complicate interpretation of disease susceptibility in our mice is the gene encoding the capsaicin receptor, Trpv1 (73.0 Mb), which lies within the congenic interval in our strain (Figure 1A). Trpv1 was recently shown to be polymorphic in NOD mice when compared with B6 (43). Destruction of capsaicin-sensitive neurons in NOD mice protected them from severe, invasive insulitis and resulted in improved insulin sensitivity. Furthermore, replacement of the NOD Trpv1 allele with that from the B6 strain using congenic NOD.B6-ldd4 mice produced phenotypes similar to those seen in capsaicin-treated NOD mice, leading these investigators to suggest that this gene may be a good candidate for the ldd4.1 locus mapped using crosses between these two strains.

Based on microsatellite mapping, the Trpv1 allele present in our final NOD congenic strain is derived from the C57BL/6 mouse and, therefore, must be considered a potential confounding factor in these studies. However, there remains significant controversy about the relationship of Trpv1 variants to the development of diabetes in NOD mice (44). While a decrease in insulitis and diabetes was seen after capsaicin treatment of NOD mice, functional abnormalities in the treated mice were limited to demonstrations of insulin resistance and poor calcium flux in neurons. Attempts to link Trpv1 variants directly to autoimmune diabetes using the NOD-ldd4 mouse strains produced by Grattan et al. are complicated by the recent demonstration that these strains are contaminated by C57BL/6 alleles across the powerful ldd5 interval on chromosome 1(45). Thus, direct evidence that Trpv1 participates in protecting these mice from autoimmune diabetes is lacking. Dissection of our congenic interval by further recombination will be required to determine whether Trpv1 may contribute to the striking diabetes resistance in our congenic strain. This effort will be complemented by analysis of disease susceptibility in NOD-ldd4 mice lacking contaminating C57BL/6 alleles at the loci contributing to ldd5 that are currently under construction at the Type 1 Diabetes Repository (E. H. Leiter, personal communication).

In order to begin to determine the mechanism(s) by which diabetes is prevented
in NOD-Alox15null congenic mice, we studied the role of several key immune cells involved in the infiltration of the pancreatic islets over the course of diabetes pathogenesis. Insulitis in NOD mice is initiated by infiltration of antigen presenting cells, such as macrophages and dendritic cells (18). Our data show that 4-week-old female NOD-Alox15null mice carry markedly reduced macrophage numbers in and around the islets, compared to age-matched NOD female controls. The mechanism for this reduction in islet-associated macrophages is not clear. However, accumulating evidence suggests that the 12/15-LO product, 12(S)-HETE, can up-regulate pro-inflammatory cytokine and chemokine production in macrophages. In preliminary studies, we evaluated selected pro-inflammatory cytokine and chemokine levels, including MCP-1 and the central pro-inflammatory cytokine IL-12, in thioglycolate-induced peritoneal macrophages, using quantitative RT-PCR. Monocyte chemoattractant 1 (MCP-1), which recruits macrophages and other hematopoietic lineages to sites of inflammation, was increased by 85% in NOD macrophages relative to those from NOD-Alox15null mice. Similarly, IL-12p40 was highly expressed in NOD macrophages but virtually undetectable in the knockout strain, suggesting that both macrophage migration and activation were likely to be defective in these mice (N.A.M., unpublished observations).

Once insulitis has been established in NOD mice, several lines of evidence suggest that β-cell damage leading to insulin deficiency occurs in parallel with decreases in the number and/or function of Foxp3+ regulatory T cells (reviewed in (46)). Although we found that CD4+ T cells are strikingly decreased in the pancreas of NOD-Alox15null mice, these mice exhibit increased numbers of Foxp3+ cells in the peri-islet infiltrates. This observation suggests that the absence of 12/15-LO activity may allow enhanced production and recruitment of regulatory T cells to the pancreas while limiting the recruitment of potential effector cells. In ongoing studies, we are investigating the possibility that enhanced regulatory cell activity can be linked to altered macrophage function in these congenic mice.

In summary, data from the NOD-Alox15null mouse suggests an important role for 12/15-LO in conferring susceptibility to autoimmune diabetes in NOD mice. The demonstration that islet-associated activated macrophages are markedly decreased in NOD-Alox15null mice prior to the onset of significant infiltration by T lymphocytes strongly suggests that 12/15-LO, or one of its products, is essential for disease initiation through its pro-inflammatory effects on macrophages, perhaps leading to decreased recruitment and/or survival of Foxp3+ regulatory cells. Whether or not the human homologue can be shown to play a role in disease susceptibility, we postulate that pharmacological blockade of
either 12/15-LO activity or signaling downstream of a 12/15-LO-derived lipid mediator could provide a new approach to protecting β-cells from immune injury through alterations in the selective recruitment of regulatory vs. effector cells. There are currently no compounds available for testing in vivo that specifically inhibit 12/15-LO and have a favorable long-term toxicity profile (54,55). However the data proposed in this study would suggest a possible clinical role for a specific and safe 12/15-LO inhibitor for use in clinical trials.

ACKNOWLEDGMENTS
This work was supported by the following grants: NIH RO1 DK55240; DERC and Animal Characterization Core and Cell and Islet Isolation Core Facilities at UVA DK063609; Institutional Diabetes Training Grant DK007320-29. Data presented in abstract form at the 67th American Diabetes Association Scientific Sessions in 2007.
REFERENCES


Protection from diabetes by deletion of 12/15 lipoxygenase


Protection from diabetes by deletion of 12/15 lipoxygenase

Table 1. Fasting Blood Glucose and Plasma Insulin in NOD and NOD-\textit{Alox15}^{null} Mice

<table>
<thead>
<tr>
<th>Genotype</th>
<th>(N)</th>
<th>Blood glucose [mg/dL]</th>
<th>Insulin [ng/ml]</th>
<th>HOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOD</td>
<td>4</td>
<td>80 +/- 6</td>
<td>0.13 +/- 0.037</td>
<td>0.71 +/- 0.165</td>
</tr>
<tr>
<td>NOD-\textit{Alox15}^{null}</td>
<td>5</td>
<td>74 +/- 10</td>
<td>0.17 +/- 0.047</td>
<td>0.82 +/- 0.208</td>
</tr>
<tr>
<td>\textit{P-value}</td>
<td></td>
<td></td>
<td>0.622</td>
<td>0.559</td>
</tr>
</tbody>
</table>
Table 2. Insulitis scores

<table>
<thead>
<tr>
<th>Pancreatic histology</th>
<th>NOD</th>
<th>NOD-Alox15null</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Periductular infiltrate (range: 0-3)</td>
<td>1.9 (±0.34)</td>
<td>0.8 (±0.19)</td>
<td>6.9 x 10^-3</td>
</tr>
<tr>
<td>Insulitis (range: 0-3)</td>
<td>2.6 (±0.14)</td>
<td>0.9 (±0.25)</td>
<td>0.2 x 10^-3</td>
</tr>
<tr>
<td>Islet mass (range: 0-1)</td>
<td>0.3 (±0.11)</td>
<td>0.8 (±0.09)</td>
<td>1.3 x 10^-3</td>
</tr>
<tr>
<td>β-cell granulation (range: 0-100)</td>
<td>31.1 (±12.2)</td>
<td>92.7 (±4.25)</td>
<td>0.2 x 10^-4</td>
</tr>
<tr>
<td>Total score (mass x granulation)</td>
<td>13.0 (±7.08)</td>
<td>72.5 (±9.42)</td>
<td>0.2 x 10^-3</td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

Figure 1.
A) Location of the fragment introgressed to generate the NOD-Alox15null congenic strain. Black intervals represent confirmed homozygosity for B6;129S2 from the donor B6,129S2-Alox15mtFun strain; light gray intervals, indeterminate regions containing recombination endpoints for the congenic interval; white intervals, regions derived from the congenic background strain.

B) Intervals defining sub-loci for Idd4 in congeneric mouse strains.
I) map of NOD-Alox15null mice (this report); II) composite map from NOD-Idd4A and NOD-Idd4B (7), showing localization of Idd4.1 and Idd4.2; III) composite map of NOD contributions to informative NOR.Idd4R3 and NOR.Idd4R3 congenic lines (42) and IV) map of NOR.Idd4R3, showing localization of Idd4.3 (6). Black intervals represent confirmed homozygosity for donor alleles: B6;129S2 in panel I, B6 in panel II, NOD in panel III; white intervals, regions derived from the congenic background strain; light gray intervals, indeterminate regions containing recombination endpoints. In panel III, dark gray intervals represent known NOD-derived regions in informative congenic lines.

Figure 2 A-B. Disease incidence in NOD-Alox15null mice compared to NOD mice.
A) Females, N=40; B) Males, N=34. Filled symbols: NOD-Alox15null, open symbols: NOD.

Figure 2 C-D. Confirmation of 12/15-LO functional deletion.
Comparison of expression of 12/15-LO in peritoneal exudate macrophages from NOD and NOD-Alox15null mice. C) Immunoblot D) Real-time quantitative RT-PCR

Figure 3. Glucose Tolerance Test results for NOD and NOD-Alox15null mice
Female NOD (black square, n = 5) and NOD-Alox15null (open triangle, n = 5) mice at 8 months of age were subjected to a glucose tolerance test. Data points represent mean blood glucose values +/- SE. Differences in blood glucose levels were statistically significant over the entire test period (p<0.0001 by two-way ANOVA).

Figure 4. Aldehyde Fuchsin staining of the islets
Fourteen non-diabetic female NOD-Alox15null mice and 10 non-diabetic NOD females were evaluated for insulitis and beta cell granulation at 30 weeks of age. Pancreata were stained with aldehyde fuchsin and examined by standard light microscopy. A. Representative section showing a well preserved islet in a NOD-Alox15null mouse. B. A representative example of an infiltrated islet seen in an age-matched, non-diabetic NOD mouse.

Figure 5. Immunofluorescent staining of frozen pancreatic sections from NOD and NOD-Alox15null islets.
Representative sections from 9.5-week-old NOD (A) or NOD-Alox15null mice (B) and 30+-week-old NOD (C) or NOD-Alox15null mice (D) were stained with antibodies against insulin (red) and CD4 (green), as well as Hoechst dye (blue, nuclear staining). Panels E (NOD) and F (NOD-Alox15null) show representative sections from 30+-week-old mice co-stained for insulin (green), Foxp3 (red), and Hoechst (blue).

Figure 6. Islet-associated activated macrophages
Pancreata from 4-week-old NOD (A) and NOD-Alox15null (B) mice were stained for Mac-2 (brown) and blindly scored for degree of infiltration. Sections shown are representative of the results from 4 individual mice from each strain.
Protection from diabetes by deletion of 12/15 lipoxygenase

FIGURE 1

A

L-128
L-4/L-13
L-5/1R-1
GM-CSF
C3

Lipoxygenase cluster 1
APRIL/TALL2
Mφ gaINAC lactin 1/2
Lipoxygenase cluster 2
CXCL16
C1q binding protein

Alox16 (12/15-lipoxygenase, leukocyte type)

B

I
II
III
IV

D11Mit188
D11Mit314
Csf2
D11Mit64
D11Mit177
D11Mit30
D11Mit30
D11Mit41
D11Mit79
Alox15
Alox12
Alox12

lbd4.1
lbd4.1
lbd4.3
lbd4.2

D11Mit325
D11Mit245
D11Mit325
D11Mit41

D11Mit189
D11Mit64
D11Mit177

D11Mit199

G-CSF
Retinoic acid receptor α
CCR7

Stat3/6A/6B cluster
FIGURE 2

A. Females

B. Males

Protection from diabetes by deletion of 12/15 lipoxygenase
Protection from diabetes by deletion of 12/15 lipoxygenase

C

NOD-Alox15<sup>null</sup>

NOD

12/15-LO

Actin

D

12/15-LO mRNA in NOD vs. NOD-Alox15<sup>null</sup>

Fold difference

12/15-LO

NOD

NOD-Alox15<sup>null</sup>
FIGURE 3

Glucose Tolerance

- NOD (♀)
- NOD-Alox15null

Blood Glucose [mg/dl]

Time (min)
FIGURE 4

Protection from diabetes by deletion of 12/15 lipoxygenase
FIGURE 5

Protection from diabetes by deletion of 12/15 lipoxygenase

NOD islets  \hspace{1cm}  NOD-\textit{Alox15}\textsuperscript{null} islets

CD4 (green), insulin (red), DAPI (blue)

A
9.5 wks

B

C
30 wks

D

Foxp3 (red), insulin (green), DAPI (blue)

E
30 wks

F
Protection from diabetes by deletion of 12/15 lipoxygenase

FIGURE 6

A. NOD islets at 4 weeks

B. NOD-Alox15null islets at 4 weeks postnatal